JNPMEDI Signs Strategic Partnership Agreement with Phantomics
JNPMEDI and Phantomics signed a strategic partnership on the 27th for cooperation between their solutions. Phantomics is an AI company specializing in medical image processing and diagnosis.
In this agreement, the two companies promised business partnership and cooperative research for the collection and management of medical data and finding imaging biomarkers through medical image analysis and data work.
Phantomics is a start-up founded in 2019 by Byung Wook Choi (CEO), and Pan Ki Kim, CEO, and research assistant professors of Yonsei University."Myomics," its AI heart diagnosis assistance software, is a solution approved by the Korean Ministry of Food and Drug Safety and the U.S. FDA earlier this year.
Jingon Kim, head of business development at JNPMEDI, said, "With Phantomics’ solution which uses AI to automatically analyzes changes in biomarkers for cardiovascular functions, and JNPMEDI's solution to manage and analyze captured data, the partnership is expected to predict patients' therapeutic response with improved safely and accurately."